4.7 Review

Treating metastatic cancer with nanotechnology

Journal

NATURE REVIEWS CANCER
Volume 12, Issue 1, Pages 39-50

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nrc3180

Keywords

-

Categories

Funding

  1. Misrock Foundation
  2. Damon Runyon Cancer Research Foundation
  3. US National Institutes of Health (NIH) [K99-CA151968]
  4. National Defense Science and Engineering Graduate fellowship
  5. National Science Foundation
  6. MIT
  7. MIT-Harvard Center of Cancer Nanotechnology Excellence (CCNE) for NIH [U54CA151884, EB000244]
  8. NATIONAL CANCER INSTITUTE [U54CA151884, K99CA151968] Funding Source: NIH RePORTER
  9. NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000244, R37EB000244] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Metastasis accounts for the vast majority of cancer deaths. The unique challenges for treating metastases include their small size, high multiplicity and dispersion to diverse organ environments. Nanoparticles have many potential benefits for diagnosing and treating metastatic cancer, including the ability to transport complex molecular cargoes to the major sites of metastasis, such as the lungs, liver and lymph nodes, as well as targeting to specific cell populations within these organs. This Review highlights the research, opportunities and challenges for integrating engineering sciences with cancer biology and medicine to develop nanotechnology-based tools for treating metastatic disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available